HOSPITAL UNIVERSITARIO RUBER
Departamento
Universidad Complutense de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (21)
2024
-
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2233-2244
2023
-
Guided Genioplasty: Comparison between Conventional Technique and Customized Guided Surgery
Journal of Personalized Medicine, Vol. 13, Núm. 12
2022
-
Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases
Cancers, Vol. 14, Núm. 5
-
Histopathology of Dermatologic Complications of Tattoos
American Journal of Dermatopathology, Vol. 44, Núm. 9, pp. 632-649
-
Metataxonomic Analysis of Milk Samples From SARS-CoV-2-Positive and SARS-CoV-2-Negative Women
Frontiers in Nutrition, Vol. 9
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64
2021
-
Immediate Pre-Partum SARS-CoV-2 Status and Immune Profiling of Breastmilk: A Case-Control Study
Frontiers in Immunology, Vol. 12
-
Mother's Bed Incline and Desaturation Episodes in Healthy Term Newborns during Early Skin-to-Skin Contact: A Multicenter Randomized Controlled Trial
Neonatology, Vol. 118, Núm. 6, pp. 702-709
-
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961
2018
-
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824
-
Tecnologías de la Información y la Comunicación (TIC): abuso de Internet, videojuegos, teléfonos móviles, mensajería instantánea y redes sociales mediante el MULTICAGE-TIC
Adicciones: Revista de socidrogalcohol, Vol. 30, Núm. 1, pp. 19-32
2016
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390
2015
-
Exercise triggers ARVC phenotype in mice expressing a disease-causing mutated version of human plakophilin-2
Journal of the American College of Cardiology, Vol. 65, Núm. 14, pp. 1438-1450
2014
-
A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21
WAF1/CIP1
) Degradation
PLoS Genetics, Vol. 10, Núm. 10
-
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer
Journal of Clinical Oncology, Vol. 32, Núm. 32, pp. 3626-3634
-
β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes
Basic Research in Cardiology, Vol. 109, Núm. 4